Shortened time to neuromuscular recovery with lower doses of rocuronium in elderly patients

Dan Med J. 2024 May 13;71(6):A09230578. doi: 10.61409/A09230578.

Abstract

Introduction: The effect of neuromuscular blocking agents may be reversed by administration of neostigmine, when two twitches are present using train-of-four (TOF) stimulation. However, in elderly patients, limited data are available about when to administer neostigmine. We hypothesised that time to two twitches after TOF (TOF-2) was shorter after rocuronium 0.6 mg/kg than after rocuronium 0.9 mg/kg. Also, we hypothesised that time to TOF-2 would be shorter after rocuronium 0.3 mg/kg than after rocuronium 0.6 mg/kg.

Methods: This was a secondary analysis of 50 elderly patients > 80 years; 16 patients received rocuronium 0.6 mg/kg, another 16 patients received rocuronium 0.9 mg/kg; and, finally, 18 patients received rocuronium 0.3 mg/kg. Patients received total intravenous anaesthesia, and neuromuscular block was monitored with acceleromyography.

Results: Time to TOF-2 was shorter after rocuronium 0.6 mg/kg than after rocuronium 0.9 mg/kg: 37 min. versus 59 min. (difference: 22 min. (95% confidence intervals (CI): 10 to 33 min.), p = 0.0007). Time to TOF-2 after rocuronium 0.3 mg/kg was shorter than after rocuronium 0.6 mg/kg: 19 min. versus 37 min. (difference: 18 min. (95% CI: 11 to 25 min.), p = 0.00006). However, only 33% of the patients receiving 0.3 mg/kg obtained full effect i.e. TOF-0.

Conclusion: Time to TOF-2 was shorter after rocuronium 0.6 mg/kg than after 0.9 mg/kg and shorter after rocuronium 0.3 mg/kg than after 0.6 mg/kg.

Funding: This work was supported by departmental sources.

Trial registration: This study was a secondary analysis of two clinical trials.

Clinicaltrials: gov (NCT04512313), (NCT03857750).

MeSH terms

  • Aged, 80 and over
  • Androstanols / administration & dosage
  • Anesthesia Recovery Period*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Male
  • Neostigmine* / administration & dosage
  • Neuromuscular Blockade* / methods
  • Neuromuscular Monitoring / methods
  • Neuromuscular Nondepolarizing Agents* / administration & dosage
  • Rocuronium* / administration & dosage
  • Time Factors

Substances

  • Rocuronium
  • Neuromuscular Nondepolarizing Agents
  • Neostigmine
  • Androstanols

Associated data

  • ClinicalTrials.gov/NCT04512313
  • ClinicalTrials.gov/NCT03857750